Literature DB >> 34320609

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine.

Valerie Oberhardt1,2, Hendrik Luxenburger1,3, Janine Kemming1,2, Isabel Schulien1, Kevin Ciminski4, Sebastian Giese4, Benedikt Csernalabics1, Julia Lang-Meli1,3, Iga Janowska5, Julian Staniek2,5, Katharina Wild1,6, Kristi Basho1, Mircea Stefan Marinescu1, Jonas Fuchs4, Fernando Topfstedt5, Ales Janda7, Oezlem Sogukpinar1, Hanna Hilger1, Katarina Stete1, Florian Emmerich8, Bertram Bengsch1,9, Cornelius F Waller10, Siegbert Rieg1, Tobias Boettler1,11, Katharina Zoldan1, Georg Kochs4, Martin Schwemmle4, Marta Rizzi5, Robert Thimme12, Christoph Neumann-Haefelin13, Maike Hofmann14.   

Abstract

SARS-CoV-2 spike mRNA vaccines1-3 mediate protection from severe disease as early as 10 days post prime vaccination3, when neutralizing antibodies are hardly detectable4-6. Vaccine-induced CD8+ T cells may thus be the main mediators of protection at this early stage7,8. The details of their induction, comparison to natural infection, and association with other arms of vaccine-induced immunity remain, however, incompletely understood. We show on a single epitope level that a stable and fully functional CD8+ T cell response is vigorously mobilized one week after bnt162b2 prime vaccination when circulating CD4+ T cells and neutralizing antibodies are still weakly detectable. Boost vaccination induced a robust expansion generating highly differentiated effector CD8+ T cells; however, neither the functional capacity nor the memory precursor T cell pool was affected. Compared to natural infection, vaccine-induced early memory T cells exhibited similar functional capacities but a different subset distribution. Our results indicate that CD8+ T cells are important effector cells, expanded in the early protection window after prime vaccination, precede maturation of other effector arms of vaccine-induced immunity and are stably maintained after boost vaccination.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2021        PMID: 34320609     DOI: 10.1038/s41586-021-03841-4

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  88 in total

1.  Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

2.  Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273.

Authors:  Ruth R Hagen; Jet van den Dijssel; Lisan H Kuijper; Christine Kreher; Thomas Ashhurst; S Marieke van Ham; Anja Ten Brinke; Carolien E van de Sandt; Niels J M Verstegen; Laura Y L Kummer; Maurice Steenhuis; Mariel Duurland; Rivka de Jongh; Nina de Jong; C Ellen van der Schoot; Amélie V Bos; Erik Mul; Katherine Kedzierska; Koos P J van Dam; Eileen W Stalman; Laura Boekel; Gertjan Wolbink; Sander W Tas; Joep Killestein; Zoé L E van Kempen; Luuk Wieske; Taco W Kuijpers; Filip Eftimov; Theo Rispens
Journal:  Elife       Date:  2022-07-15       Impact factor: 8.713

3.  Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity.

Authors:  Ann Cavers; Matthias Christian Kugler; Yesim Ozguler; Arshed Fahad Al-Obeidi; Gulen Hatemi; Beatrix M Ueberheide; Didar Ucar; Olivier Manches; Johannes Nowatzky
Journal:  Ann Rheum Dis       Date:  2022-08-03       Impact factor: 27.973

4.  Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.

Authors:  Michal Podrazil; Pavla Taborska; Dmitry Stakheev; Michal Rataj; Jan Lastovicka; Alena Vlachova; Petr Pohunek; Jirina Bartunkova; Daniel Smrz
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

5.  Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center.

Authors:  Milton C Chew; Shaan Wiryasaputra; Meihui Wu; Wei Boon Khor; Anita S Y Chan
Journal:  Front Med (Lausanne)       Date:  2022-06-22

6.  Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients.

Authors:  Bernice Ling Zhi Oh; Nicole Tan; Ruklanthi de Alwis; Kamini Kunasegaran; Zhiwei Chen; Michelle Poon; Esther Chan; Jenny G H Low; Allen Eng Juh Yeoh; Antonio Bertoletti; Nina Le Bert
Journal:  Blood       Date:  2022-07-14       Impact factor: 25.476

7.  SARS-CoV-2-specific T cell memory with common TCRαβ motifs is established in unvaccinated children who seroconvert after infection.

Authors:  Louise C Rowntree; Thi H O Nguyen; Lukasz Kedzierski; Melanie R Neeland; Jan Petersen; Jeremy Chase Crawford; Lilith F Allen; E Bridie Clemens; Brendon Chua; Hayley A McQuilten; Anastasia A Minervina; Mikhail V Pogorelyy; Priyanka Chaurasia; Hyon-Xhi Tan; Adam K Wheatley; Xiaoxiao Jia; Fatima Amanat; Florian Krammer; E Kaitlynn Allen; Sabrina Sonda; Katie L Flanagan; Jaycee Jumarang; Pia S Pannaraj; Paul V Licciardi; Stephen J Kent; Katherine A Bond; Deborah A Williamson; Jamie Rossjohn; Paul G Thomas; Shidan Tosif; Nigel W Crawford; Carolien E van de Sandt; Katherine Kedzierska
Journal:  Immunity       Date:  2022-06-08       Impact factor: 43.474

8.  Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes.

Authors:  Ayesa Syenina; Esther S Gan; Justin Z N Toh; Ruklanthi de Alwis; Lowell Z Lin; Christine Y L Tham; Jia Xin Yee; Yan Shan Leong; Huizhen Sam; Charlene Cheong; Yii Ean Teh; Ian L E Wee; Dorothy H L Ng; Kuan Rong Chan; Jean X Y Sim; Shirin Kalimuddin; Eugenia Z Ong; Jenny G Low; Eng Eong Ooi
Journal:  PLoS Biol       Date:  2022-05-31       Impact factor: 9.593

9.  The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study.

Authors:  Daisuke Jubishi; Koh Okamoto; Kensuke Hamada; Takashi Ishii; Hideki Hashimoto; Takayuki Shinohara; Marie Yamashita; Yuji Wakimoto; Amato Otani; Naoko Hisasue; Mahoko Ikeda; Sohei Harada; Shu Okugawa; Kyoji Moriya; Shintaro Yanagimoto
Journal:  Hum Vaccin Immunother       Date:  2022-03-25       Impact factor: 4.526

10.  SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells.

Authors:  Anastasia A Minervina; Mikhail V Pogorelyy; Allison M Kirk; Jeremy Chase Crawford; E Kaitlynn Allen; Ching-Heng Chou; Robert C Mettelman; Kim J Allison; Chun-Yang Lin; David C Brice; Xun Zhu; Kasi Vegesana; Gang Wu; Sanchit Trivedi; Pratibha Kottapalli; Daniel Darnell; Suzanne McNeely; Scott R Olsen; Stacey Schultz-Cherry; Jeremie H Estepp; Maureen A McGargill; Joshua Wolf; Paul G Thomas
Journal:  medRxiv       Date:  2022-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.